Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CCR4 | P51679 | 13/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419211 | 0.90 | RXFP1 (0.70) | RXFP1ALDH1A1L3MBTL1CCR4KDM4E | |
| SCHEMBL4684562 | 0.87 | CCR4 (0.58) | RXFP1ALDH1A1L3MBTL1CCR4 | |
| SCHEMBL4684020 | 0.84 | CCR4 (0.55) | RXFP1ALDH1A1L3MBTL1CCR4 | |
| SCHEMBL4683826 | 0.83 | CCR4 (0.72) | CCR4 | |
| SCHEMBL2422617 | 0.81 | SLC40A1 (0.56) | RXFP1ALDH1A1L3MBTL1CCR4SLC40A1 | |
| SCHEMBL2304255 | 0.80 | RXFP1 (0.76) | RXFP1ALDH1A1L3MBTL1CCR4KDM4E | |
| SCHEMBL2425236 | 0.80 | RXFP1 (0.71) | RXFP1ALDH1A1L3MBTL1CCR4KDM4E | |
| SCHEMBL1732746 | 0.78 | CCR4 (0.71) | CCR4 | |
| SCHEMBL4682187 | 0.76 | CCR4 (0.69) | CCR4 | |
| SCHEMBL1731259 | 0.75 | CCR4 (0.69) | CCR4SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012052420-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | MERCK SERONO S.A. GENEVA (CH) | 2012-04-26 | — | — | WO | disclosed |
| EP-1660461-B1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1660461-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021513-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | CCL2, CCL11, CCR2 | RXFP1 2588/4885ALDH1A1 2310/4885L3MBTL1 4132/4885 |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | STS, NQO2, ASNS | RXFP1 3539/4885ALDH1A1 2918/4885L3MBTL1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.